Research Coverage on Small and Micro-Cap Companies, Zacks Small Cap Research

Zacks Small Cap Research

Zacks Small Cap Research provides research coverage on small- and micro-cap companies that are “under-followed” or “under-valued” by Wall Street. We produce high quality equity research for the institutional and retail investor on microcap firms we believe are well positioned for future growth. The Zacks SCR analyst team has an average of 20 years of experience in investment research. We conduct significant due diligence in an effort to maintain the highest quality small-cap universe.

Research Coverage on Small and Micro-Cap Companies

Equity Bottom-Up

<ul><li>On August 9, 2024, Edesa Biotech, Inc. (EDSA) announced financial results for the third quarter of fiscal year 2024 that ended June 30, 2024 and provided a business update.</li><li>In June 2024, the company announced that EB05 was selected by the Biomedical Advanced Research and Development Authority (BARDA) for evaluation in a U.S. government-funded clinical trial in hospitalized adult patients with acute respiratory distress syndrome (ARDS).</li><li>The data from this study could provide additional support for expanding the use of EB05, with the ultimate goal being an approval for EB05 as a standard-of-care therapy for all-cause ARDS.</li></ul>

On August 9, 2024, Edesa Biotech, Inc. (EDSA) announced financial results for the third quarter of fiscal year 2024 that ended June 30, 2024 and provided a business update.In June 2024, the company announced that EB05 was selected by the Biomedical Advanced Research and Development Authority (BARDA) for evaluation in a U.S. government-funded clinical trial in hospitalized adult patients with acute respiratory distress syndrome (ARDS).The data from this study could provide additional support for expanding the use of EB05, with the ultimate goal being an approval for EB05 as a standard-of-care therapy for all-cause ARDS.

EDSA: EB05 Selected for BARDA-Funded Study in ARDS 